Revalia Bio Inc. has successfully raised $14.5 million in a seed funding round to launch their innovative ‘Human Data Trials’ platform. This new approach to pre-clinical research aims to provide drug developers with early and predictive insights by utilizing real, functional human organs. The funding round was co-led by America’s Frontier Fund and Sierra Ventures, with notable participation from Roger Ferguson, former Vice Chair of the U.S. Federal Reserve and a member of Alphabet’s Board of Directors. This brings Revalia’s total funding to $19.5 million.
The traditional drug development model faces challenges, with over 90% of drug candidates failing to reach market approval due to ineffective translation from preclinical models to human biology. Revalia addresses these issues by offering on-demand access to functional human data through rigorous testing on perfused human organs. These organs, not suitable for clinical transplant, are donated with informed consent and maintained under clinical conditions, enhancing the accuracy of preclinical data and reducing development costs.
Greg Tietjen, co-founder and CEO of Revalia Bio, emphasizes the need for a new paradigm in drug development that prioritizes real human data over approximations. The company’s proprietary perfusion technology revives and sustains donated human organs, allowing biotech and pharmaceutical companies to evaluate new therapies more accurately. This approach not only improves preclinical data accuracy but also reduces risks to living patients.
Revalia’s platform integrates data from perfused human organs, donor medical histories, and high-resolution digital analytics, offering valuable insights into discovery, safety, biodistribution, and efficacy. By collaborating with academic medical centers and organ procurement organizations, Revalia transforms donated, non-transplantable organs into research systems that accelerate therapeutic discovery. This initiative allows donors and their families to contribute to the advancement of life-saving medicines.
Since its commercial launch in 2023, Revalia has quadrupled its revenue and secured partnerships with two of the world’s top 10 pharmaceutical companies. The company has also developed a pioneering human lung cancer model and achieved significant breakthroughs in organ perfusion, including a four-day kidney protocol.
Revalia was founded by a diverse team of scientists, entrepreneurs, and operators, including CEO Greg Tietjen, a former Yale professor and expert in perfusion science, and Jenna DiRito, who has extensive experience in human organ research infrastructure. The team is complemented by clinical and operational experts Kourosh Saeb-Parsy, Peter Buniak, and Helen Hughes, with Milad Alucozai, a neuroscientist and first investor, joining to help scale the company.
Looking forward, Revalia aims to establish itself as the foundational infrastructure for Human-Centered Drug Development, shifting the focus from animal models to human-first decision-making. The company’s long-term vision is to provide the necessary infrastructure and insights to transform drug development into a truly human-centered system, addressing real-world challenges faced by healthcare providers.
